Adenocarcinoma de pulmón pobremente indiferenciado. A propósito de un caso

Simple item page
dc.creatorMéndez Roman, Ramona
dc.creatorGuzmán Valerio, Lissabel Altagracia
dc.creatorSeverino Cruz, Giovanny Masiel
dc.date2019-04-11
dc.date.accessioned2020-09-09T19:43:54Z
dc.date.available2020-09-09T19:43:54Z
dc.descriptionCancer is one of the leading causes of death in the world. It is the most frequent neoplasm and with the highest mortality in both sexes in developed countries. Its overall prognosis is poor with a 5-year total survival of 15%. The risk factors for PC are diverse, but they emphasize smoking, both active and passive; radiation exposure by radon gas; diet; exposure to chemical compounds such as asbestos, arsenic, vinyl chloride, nickel chromate, chloromethyl ether, among many other substances. CP is considered as a sentinel disease of smoking for the following reasons: 1. Tobacco smoking is the risk factor present in 90% of patients with PC. 2. The risk of getting sick or dying from PC in smokers increases dramatically after 40 years of age. 3. CP mortality rates increase after 40 years of age, directly related to tobacco use. 4. After 10 years of abstinence, the relative risk of developing CP is reduced by 50% compared to persistence in habit. Non-small cell lung carcinoma (CNCP) accounts for 80-85% of PC. It mainly includes the following histological types: epidermoid, adenocarcinoma and large cell types. At presentation only 25% are localized stages, and 35% are locally advanced stages (stage III or IV). Approximately 80% of patients with CNCP present metastatic disease in some of its evolutionary phases: 30-40% at diagnosis, 50% due to recurrence of stages I-II and 80% due to progression or relapse of stages III, and its Survival is very poor. Small cell lung carcinoma (PCC) constitutes approximately 15-20% of lung neoplasms. Approximately 60-70% of patients have disseminated disease at the time of diagnosis.en-US
dc.descriptionEl cáncer es una de las principales causas de muerte en el mundo. Es la neoplasia más frecuente y con mayor mortalidad en ambos sexos en los países desarrollados. Su pronóstico global es malo con una supervivencia total a los 5 años del 15%. Los factores de riesgo para el CP son diversos, pero destacan el tabaquismo, tanto activo como pasivo; exposición a radiación por gas radón; dieta; exposición a compuestos químicos como asbestos, arsénico, cloruro de vinilo, cromato de níquel, clorometilo de éter, entre muchas otras sustancias más. El CP se considera como enfermedad centinela del tabaquismo por las siguientes razones: 1. Fumar tabaco es el factor de riesgo presente en 90% de los pacientes con CP. 2. El riesgo de enfermar o morir por CP en fumadores aumenta drásticamente después de los 40 años de edad. 3. Las tasas de mortalidad por CP aumentan después de los 40 años de edad, en relación directa con el consumo de tabaco. 4. Después de 10 años de abstinencia, el riesgo relativo de desarrollar CP se reduce 50% en comparación con la persistencia en el hábito. El carcinoma no de células pequeñas de pulmón (CNCP) supone el 80-85% de los CP. Incluye fundamentalmente, los siguientes tipos histológicos: epidermoide, adenocarcinoma y de células grandes. A su presentación sólo el 25% son estadios localizados, y un 35% son estadios localmente avanzados (estadio III o IV). Aproximadamente el 80% de los pacientes con CNCP presentan enfermedad metastásica en alguna de sus fases evolutivas: 30-40% al diagnóstico, 50% por recidiva de los estadios I-II y 80% por progresión o recaída de los estadios III, y su supervivencia es muy pobre. El carcinoma de células pequeñas de pulmón (CCP) constituye aproximadamente el 15-20% de las neoplasias pulmonares. Aproximadamente el 60- 70% de los pacientes tienen enfermedad diseminada en el momento del diagnóstico.es-ES
dc.formatapplication/pdf
dc.formattext/html
dc.identifierhttps://revistas.intec.edu.do/index.php/cisa/article/view/1335
dc.identifier10.22206/cysa.2019.v3i1.pp79-88
dc.identifier.urihttps://repositoriobiblioteca.intec.edu.do/handle/123456789/2739
dc.languagespa
dc.publisherIntituto Tecnológico de Santo Domingo (INTEC)es-ES
dc.relationhttps://revistas.intec.edu.do/index.php/cisa/article/view/1335/1698
dc.relationhttps://revistas.intec.edu.do/index.php/cisa/article/view/1335/1714
dc.relation/*ref*/Beckles MA, Spiro SG, Colice GL, Rudd RM. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest 2003; 123: 97S-104S.
dc.relation/*ref*/Campos Parra AD, Cruz Risco G, Arrieta O. Personalización del tratamiento del cáncer de pulmón de células no pequeñas. Rev Invest Clin [Internet]. Jul-Ago 2012 [citado 28 Ene 2016];64(4):[aprox. 8 p.].
dc.relation/*ref*/Lima Guerra A, Gassiot Nuño C, Ramos Quevedo A, Rodríguez Vázquez JC, Cabanes Varona L, Morales Sánchez L, et al. Conducta diagnóstica y pronóstico en pacientes con carcinoma pulmonar de células no pequeñas en estadios quirúrgicos. Rev Cubana Med [Internet]. 2012 [citado 28 Ene 2016];51(1):[aprox. 12 p.].
dc.relation/*ref*/Husain AN. Pulmón. En: Kumar V, Abbas AK, Fausto N, Aster JC, editores. Robbins y Cotran. Patología estructural y funcional. 8 ed. Barcelona: Elsevier; 2010. p. 677- 738.
dc.relation/*ref*/Stricker TP, Kumar V. Neoplasias. En: Kumar V, Abbas AK, Fausto N, Aster JC, editores. Robbins y Cotran. Patología estructural y funcional. 8 ed. Barcelona: Elsevier; 2010. p. 259-330.
dc.relation/*ref*/Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003; 123: 115S-128S.
dc.relation/*ref*/Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-7.
dc.relation/*ref*/Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123: 137S-146S.
dc.relation/*ref*/Detterbeck FC, Falen S, Rivera MP, Halle JS, Socinski MA. Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004; 125: 2300-8.
dc.relation/*ref*/Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U, Mullet D, Atkins M. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 2002; 122: 1918-24.
dc.relation/*ref*/Toloza EM, Harpole L, Detterbeck F, McCrory DC. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123: 157S-166S.
dc.relation/*ref*/Herth F, Becker HD. New aspects in early detection and local staging of early lung cancer. Lung Cancer 2001; 34: S7-11.
dc.relation/*ref*/Ginsberg RJ, Rice TW, Goldberg M, Waters PF, Schmocker BJ. Extended cervical mediastinoscopy. A single staging procedure for bronchogenic carcinoma of the left upper lobe. J Thorac Cardiovasc Surg 1987; 94: 673-8.
dc.relation/*ref*/Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F; American College of Chest Physicians. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003; 123: 147S-156S.
dc.relation/*ref*/Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97: 1052-8.
dc.relation/*ref*/Ferrigno D, Buccheri G. Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer. Chest 1994; 106: 1025-9.
dc.relation/*ref*/Earnest F 4th, Ryu JH, Miller GM, Luetmer PH, Forstrom LA, Burnett OL, et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection—pilot study. Radiology 1999; 211: 137-45.
dc.relation/*ref*/Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer. A metaanalysis. Am J Respir Crit Care Med 1995; 152: 225-30.
dc.relation/*ref*/Sharples LD, Jackson C, Wheaton E, Griffith G, Annema JT, Dooms C, et al. Clinical effectiveness and cost- effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: Results from de ASTER randomized controlled trial. Health Technol Assess. 2012;16:1-75
dc.rightsDerechos de autor 2019 Ciencia y Saludes-ES
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/4.0es-ES
dc.sourceScience and Health; Vol 3 No 1 (2019): Science and Health, january-april; 79-88en-US
dc.sourceCiencia y Salud; Vol. 3 Núm. 1 (2019): Ciencia y Salud, enero-abril; 79-88es-ES
dc.source2613-8824
dc.source2613-8816
dc.source10.22206/cysa.2019.v3i1
dc.subjecttumoren-US
dc.subjectmalignanten-US
dc.subjectadenocarcinomaen-US
dc.subjectlungen-US
dc.subjectundifferentiateden-US
dc.subjecttumores-ES
dc.subjectmalignoes-ES
dc.subjectadenocarcinomaes-ES
dc.subjectpulmónes-ES
dc.subjectindiferenciadoes-ES
dc.titlePoultry indiferentiated lung adenocarcinoma. A case presentationen-US
dc.titleAdenocarcinoma de pulmón pobremente indiferenciado. A propósito de un casoes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
Files
Collections
Articulos CS